News & Insights

2021 Laureate Award Recognizes Exceptional Contributions in Overcoming Vision Loss November 11, 2021, Rochester, MI and New Orleans, LA – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced that company co-founder Dr. Michael T. Trese, received the prestigious Laureate Award from the American Academy...

Advancing treatments for retinal-related vision loss and other neurosensory diseases Rochester, MI and Chapel Hill, NC, August 12, 2021 – Retinal Solutions, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced it has changed its name to Caeregen Therapeutics, LLC. The progression into pharmaceutical development of Noregen™, the...

Disorders of vascular structure and function play a central role in a wide variety of CNS diseases. Mutations in the Frizzled4 (Fz4) receptor, Lrp5 co-receptor, or Norrin ligand cause retinal hypovascularization, but the role of Norrin/Fz4/Lrp signaling in vascular development has not been defined. ...